FDA won't hold companies responsible for independent user content on their social media properties

U.S. pharmaceutical companies may have gotten off easy compared to other areas of the world, said Peter Pitts, president of the Center for Medicine in the Public Interest and a former associate commissioner at the FDA.

The European Court of Justice recently ruled that online remarks about drugs posted by a third party on the manufacturer's Web property could constitute advertising, even though the post's author has no connection with the product's manufacturer or marketer.

“That's carte blanche for an almost complete gag order on anyone who wants to discuss anything to do with medicines,” Pitts said.
Sign Up for Our Email Newsletter

RECENT NEWS

The coronavirus could help pharma reset its reputation in Washington

The coronavirus could help pharma reset its reputation in Washington

The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington....  Read more

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

Differing philosophies within and outside of government could doom the hub...  Read more

Tort bar’s newest collateral damage: Preterm babies

Tort bar’s newest collateral damage: Preterm babies

Lawsuits allege links between intestinal disease, infant formula and human milk fortifiers...  Read more

DRUGWONKS BLOG